Thursday, February 03, 2022 5:52:13 PM
9:00a ET 2/3/2022 - Globe Newswire
Nexien BioPharma Engages Dr. Benedikt Schoser as Advisor
Mentioned: NXEN
Nexien BioPharma Inc. (OTCQB: NXEN) ("Nexien" or the "Company") today announced that it has retained Dr. Benedikt Schoser as an advisor to the Company. Dr. Schoser, who has previously served as a scientific advisor to the Company, is senior consultant at the Friedrich-Baur Institute, Department of Neurology at the Ludwig-Maximilians-University of Munich, Germany's major national referral center for rare neuromuscular diseases, and is considered one of the world's top researchers in myotonia and the treatment of myotonic dystrophy. The Company also retained regulatory counsel and is initiating discussions with a pharmaceutical company to pursue formulation development. Richard Greenberg, Nexien's CEO and Chairman of the Board, stated, "We are excited to be establishing a team to address myotonic dystrophy and myotonia. The successful completion of our recent financing enables us to recommence our myotonic dystrophy research." Greenberg added, "Nexien has already been granted a United States patent for the treatment of dystrophies and myotonia and looks forward to benefiting from the team's knowledge regarding myotonic dystrophy, while seeking to advance a drug development strategy to treat myotonic dystrophy and myotonia."
Recent NXEN News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/22/2024 07:00:39 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/30/2024 10:07:17 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/28/2024 03:58:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/28/2024 03:57:51 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 10:19:44 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/20/2024 11:19:50 AM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 02/14/2024 11:04:33 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM
Integrated Ventures Announces Partnership And Lease Agreement with Driptide Wellness - Leading Health and Wellness Provider. • INTV • Oct 29, 2024 8:45 AM